Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

Inclusion Criteria: * The patients who are able to participate in this expanded study without any interruption after completing 48 weeks treatment of LG-BVCL007 study Exclusion Criteria: * Co-infection with hepatitis C or D virus (HCV or HDV) or HIV * Decompensated liver disease * ALT \> 10 x ULN * Creatinine clearance (calculated by cockcroft-gault formula) less than 50 ml/min * Alpha-fetoprotein (AFP) value greater than or equal to 50 ng/mL, and a follow-up ultrasonography performed prior to baseline shows findings indicative of HCC * Treatment with immunomodulatory agent or corticosteroids within 6 months prior to study entry. * Pregnancy or breast-feeding * Patient is currently abusing alcohol or illicit drugs * Significant systemic illnesses other than liver diseases * Presence of other causes of liver disease * Plan for liver transplantation